0 0 0 0.00130034297150125 -0.00102601411041319 0.000768604209920755 -0.000856824504455802 -0.00365449548868001
Sign Up Today X
Thanks for submitting the form.
Stockreport

NTLA's Q3 Earnings & Revenues Beat Estimates, Pipeline in Focus [Yahoo! Finance]

Regeneron Pharmaceuticals, Inc. (REGN)  More Company Research Source: Yahoo! Finance
Last regeneron pharmaceuticals, inc. earnings: 2/6 06:30 am Check Earnings Report
US:NASDAQ Investor Relations: investor.regeneron.com
In the year-ago quarter, Intellia had incurred a loss of $1.38 per share. The company's total revenues currently comprise only collaboration revenues. Intellia reported revenues of $9.1 million for the third quarter of 2024 compared with $12 million reported in the year-ago quarter. Revenues however beat the Zacks Consensus Estimate of $8 million. The year-over-year decrease in revenues was due to a reduction in revenues related to the AvenCell license and collaboration agreement. Shares of Intellia have plunged 47.6% year to date compared with the industry's decline of 2.4%. Image Source: Zacks Investment Research Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar. Intellia's collaboration revenues beat our model estimate of $8 million. Research and development expenses totaled $123.4 million, up 8.5% from the year-ago quarter's figure. The increase was due to the advancement of lead pipeline programs. General and administrative expenses increase [Read more]
IMPACT SNAPSHOT EVENT TIME: REGN
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
REGN alerts
from News Quantified
REGN
NEWS
REGN
Earnings
REGN
Analyst Actions
REGN
SEC Filings
Stockreport

NTLA's Q3 Earnings & Revenues Beat Estimates, Pipeline in Focus [Yahoo! Finance]

Regeneron Pharmaceuticals, Inc.  (REGN) 
More Company Research Source: Yahoo! Finance
Last regeneron pharmaceuticals, inc. earnings: 2/6 06:30 am Check Earnings Report
US:NASDAQ Investor Relations: investor.regeneron.com
In the year-ago quarter, Intellia had incurred a loss of $1.38 per share. The company's total revenues currently comprise only collaboration revenues. Intellia reported revenues of $9.1 million for the third quarter of 2024 compared with $12 million reported in the year-ago quarter. Revenues however beat the Zacks Consensus Estimate of $8 million. The year-over-year decrease in revenues was due to a reduction in revenues related to the AvenCell license and collaboration agreement. Shares of Intellia have plunged 47.6% year to date compared with the industry's decline of 2.4%. Image Source: Zacks Investment Research Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar. Intellia's collaboration revenues beat our model estimate of $8 million. Research and development expenses totaled $123.4 million, up 8.5% from the year-ago quarter's figure. The increase was due to the advancement of lead pipeline programs. General and administrative expenses increase [Read more]
IMPACT SNAPSHOT
EVENT TIME:
REGN
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Don't Miss Out On The Next BIG Stock Move
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS